Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652607 | 0.91 | NR2F2 (0.54) | NPC1RAB9ASMN1; SMN2NR2F2SLC29A1 | |
| SCHEMBL12566819 | 0.91 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2NR2F2SLC29A1 | |
| SCHEMBL10242201 | 0.82 | CTSL (0.49) | NPC1RAB9ASMN1; SMN2SLC29A1CTSL | |
| SCHEMBL12566837 | 0.81 | CCNA2 (0.43) | NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL12652428 | 0.81 | BCHE (0.43) | NFKB1BLMALDH1A1CYP1A2 | |
| SCHEMBL12567224 | 0.80 | ADORA3 (0.44) | NPC1RAB9ASMN1; SMN2PAX8TSHR | |
| SCHEMBL1794568 | 0.80 | SLC29A1 (0.64) | SLC29A1ADORA3 | |
| SCHEMBL20008035 | 0.80 | ABL1 (0.50) | ABL1RIN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20008060 | 0.79 | NR2F2 (0.54) | NPC1RAB9ASMN1; SMN2NR2F2SLC29A1 | |
| SCHEMBL192286 | 0.79 | NAE1 (0.54) | CTSLADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ABL1 2833/4885RIN1 1844/4885NPC1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.